Zobrazeno 1 - 10
of 24
pro vyhledávání: '"E.Z. Chan"'
Autor:
Agata Blasiak, Anh T. L. Truong, Peter Wang, Lissa Hooi, De Hoe Chye, Shi-Bei Tan, Kui You, Alexandria Remus, David Michael Allen, Louis Yi Ann Chai, Conrad E.Z. Chan, David C. B. Lye, Gek-Yen G. Tan, Shirley G. K. Seah, Edward Kai-Hua Chow, Dean Ho
Publikováno v:
ACS Nano. 16:15141-15154
Nanomedicine-based and unmodified drug interventions to address COVID-19 have evolved over the course of the pandemic as more information is gleaned and virus variants continue to emerge. For example, some early therapies (e.g., antibodies) have expe
Autor:
H.S. Ling, Y.L. Cham, Y.Y. Oon, A.Y.Y. Fong, B.K. Chung, L.K. Thien, H.B. Chow, E.Z. Chan, H.K. Khor, D.S.T. Chan, I.X. Pang, F.E.P. Shu, K.H. Ho, C.T. Tan, K.T. Koh, S. Asri, T.K. Ong
Publikováno v:
International Journal of Cardiology. 369:4-5
Autor:
H.B. Chow, H.S. Ling, E.Z. Chan, B.K. Chung, L.K. Then, I.X. Pang, S.T. Chan, H.K. Khor, C.T. Tan, Y.Y. Oon, K.T. Koh, Y.L. Cham, A. Said, A.Y.Y. Fong, T.K. Ong
Publikováno v:
International Journal of Cardiology. 369:23-24
Autor:
B.K. Chung, E.Z. Chan, L.K. Thien, I.X. Pang, D.S.T. Chan, H.K. Khor, F.E.P. Shu, H.S. Ling, H.B. Chow, Y.H. Jong, S.Y. Soon, C.T. Tan, K.T. Koh, Y.L. Cham, A. Said, A.Y.Y. Fong, T.K. Ong, Y.Y. Oon
Publikováno v:
International Journal of Cardiology. 369:2
Autor:
H.B. Chow, H.S. Ling, E.Z. Chan, B.K. Chung, L.K. Then, I.X. Pang, H.K. Khor, S.T. Chan, C.T. Tan, K.T. Koh, Y.L. Cham, A. Said, A.Y.Y. Fong, T.K. Ong, Y.Y. Oon
Publikováno v:
International Journal of Cardiology. 369:6
Autor:
L.K. Thien, Y.L. Cham, D.S.T. Chan, H.K. Khor, E.Z. Chan, B.K. Chung, I.X. Pang, H.S. Ling, H.B. Chow, F.E.P. Shu, K.H. Ho, C.T. Tan, K.T. Koh, Y.Y. Oon, A. Said, A.Y.Y. Fong, T.K. Ong
Publikováno v:
International Journal of Cardiology. 369:3
Autor:
H.B. Chow, H.S. Ling, E.Z. Chan, B.K. Chung, L.K. Then, I.X. Pang, S.T. Chan, H.K. Khor, C.T. Tan, Y.Y. Oon, K.T. Koh, Y.L. Cham, A. Said, A.Y.Y. Fong, T.K. Ong
Publikováno v:
International Journal of Cardiology. 369:24
Autor:
David M Allen, Gek-Yen Gladys Tan, Peter Wang, Alexandria Remus, Anh T. L. Truong, Yee-Joo Tan, Raymond T. P. Lin, Agata Blasiak, Edward Kai-Hua Chow, Wee Joo Chng, Kim Tien Ng, Angeline Pei Chiew Lim, Louis Yi Ann Chai, De Hoe Chye, Dean Ho, John Wong, Conrad E.Z. Chan, David C. Lye, Swee Teng Teo, Shirley Gek Kheng Seah, Lissa Hooi
ObjectivesWe aimed to harness IDentif.AI 2.0, a clinically actionable AI platform to rapidly pinpoint and prioritize optimal combination therapy regimens against COVID-19.MethodsA pool of starting candidate therapies was developed in collaboration wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3657e0b9e1d56a1030e8d79de9129c4c
https://doi.org/10.1101/2021.06.23.21259321
https://doi.org/10.1101/2021.06.23.21259321
Autor:
Julien Lescar, Angeline T. H. Goh, Yee Hwa Wong, Rachel Zui Chih Teo, Jiawei Yap, Abbas El Sahili, Maryam Hamidinia, Kathryn J. Wood, Conrad E.Z. Chan, Nicholas R. J. Gascoigne, Tanusya M. Murali, Kiren Purushotorman, Brendon J. Hanson, Chong Wai Liew, Chien Tei Too, Anantharaman Vathsala, Yue Gu, Paul A. MacAry
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-11 (2019)
Nature Communications
Nature Communications
Our understanding of the conformational and electrostatic determinants that underlie targeting of human leukocyte antigens (HLA) by anti-HLA alloantibodies is principally based upon in silico modelling. Here we provide a biochemical/biophysical and f
Autor:
Chien-Te K Tseng, Dipti Thakkar, Boyd-Kirkup Jerome Douglas, Trevor Brasel, Paul A. MacAry, Dong Ling Wang, Jason E. Comer, Hannes Hentze, Ingram Piers, Brendon J. Hanson, Angeline P.C. Lim, Guan Siyu, Maricela Torres, Kiren Purushotorman, Damian O’Connell, Jacklyn J.Y. Neo, Guo Hui Teo, Steven K.K. Wong, Conrad E.Z. Chan, Shirley Gek Kheng Seah, Venkateshan S. Prativadibhayankara, Paul Edward Hutchinson, De Hoe Chye, Jenny G. Low, Gary S.L. Loh, Kantharaj Ethirajulu, David C. Lye, Jie Hui Lim, Pui San Wong, Barnaby Edward Young, Alan D.T. Barrett, Shane Massey
SARS-CoV-2-neutralizing antibodies are promising therapeutics for COVID-19. However, little is known about the mechanisms of action of these antibodies or their effective dosing windows. We report the discovery and development of SC31, a potent SARS-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::606850ac3cb09b13cecd9961dbe2c00e
https://doi.org/10.1101/2020.10.26.355107
https://doi.org/10.1101/2020.10.26.355107